Prothena Corp Public (PRTA) Net Margin (2012 - 2026)
Prothena Corp Public's (PRTA) quarterly Net Margin came in at 64.05% in Q1 2026, up 219259.0% year-on-year from N/an in Q1 2025, and up 100.06% quarter-over-quarter from 102580.95% in Q4 2025.
Prothena Corp Public (PRTA) Net Margin (2012 - 2026) Analysis & Trends
Prothena Corp Public's Net Margin history runs 15 years deep, the most recent figure standing at 64.05% for Q1 2026.
- On a quarterly basis, Net Margin rose 219259.0% year-over-year to 64.05% in Q1 2026; TTM through Mar 2026 was 260.79%, a 18077.0% decrease from a year earlier, with the FY2025 full-year figure at 2520.57%, down 243008.0% from the prior year.
- Net Margin advanced to 64.05% in Q1 2026 per PRTA's latest filing, from 102580.95% in the prior quarter.
- Across five years, Net Margin topped out at 64.05% in Q1 2026 and bottomed at 144478.0% in Q1 2024.
- The 5-year median for Net Margin is 2731.09% (2024), against an average of 17434.62%.
- Across the five-year window, Net Margin tumbled 14231682 bps in 2024 and jumped 14234946 bps in 2025, its largest moves.
- Year by year, Net Margin stood at 12.72% in 2022, then sank by 168003 bps to 21353.16% in 2023, then surged by 87 bps to 2731.09% in 2024, then tumbled by 3656 bps to 102580.95% in 2025, then soared by 100 bps to 64.05% in 2026.
- Per Business Quant, the three latest PRTA Net Margin figures stand at 64.05% (Q1 2026), 102580.95% (Q4 2025), and 1511.88% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Prothena Corp Public | 458.13 Mn | 128.67 Mn | - | 64.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 64.05% |
| Dec 31, 2025 | -102,580.95% |
| Sep 30, 2025 | -1,511.88% |
| Jun 30, 2025 | -2,845.41% |
| Mar 31, 2025 | -2,128.54% |
| Dec 31, 2024 | -2,731.09% |
| Sep 30, 2024 | -6,086.19% |
| Jun 30, 2024 | 50.64% |
| Mar 31, 2024 | -144,478.00% |
| Dec 31, 2023 | -21,353.16% |
| Sep 30, 2023 | 25.82% |
| Jun 30, 2023 | -1,358.57% |
| Mar 31, 2023 | -2,161.18% |
| Dec 31, 2022 | 12.72% |
| Sep 30, 2022 | -3,013.65% |
| Jun 30, 2022 | -3,145.73% |
| Mar 31, 2022 | -3,147.44% |
| Dec 31, 2021 | -2,827.82% |
| Sep 30, 2021 | 78.50% |
| Jun 30, 2021 | 45.94% |